Clinical data show that the administration of PCSK9 mAbs is associated with an approximately 60% reduction in plasma LDL-C level in patients with both heterozygous FH and non-familial PH [81,82,83,84]. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.